期刊文献+

CYP2D6*10基因多态性对托烷司琼术后止吐效果的影响 被引量:3

暂未订购
导出
摘要 目的观察CYP2D6*10基因多态性对托烷司琼术后止吐效果的影响。方法选择择期手术行全身麻醉女性患者60例(ASAⅠ~Ⅱ级),手术结束前30 min静脉给予托烷司琼5 mg,记录术后发生恶心呕吐的情况并对其进行呕吐分级。全组患者于麻醉诱导前采集静脉血3 mL,运用等位基因特异扩增法(ASA-PCR)进行CYP2D6*10基因分型,并记录患者术中循环状态、术后疼痛评分及其他不良反应的情况。结果按照变异位点筛选出野生型纯合子(wt/wt)11例(3.1%),杂合子(m/wt)25例(65%),突变型纯合子(m/m)24例(21.7%),突变纯合子患者恶心呕吐发生率低于其他两类患者(P<0.05);术中循环状态平稳、无不良反应。结论 CYP2D6*10基因多态性是个体产生对托烷司琼代谢差异的影响原因之一,其中突变纯合子类患者术后托烷司琼止吐效果较好。
出处 《广东医学》 CAS CSCD 北大核心 2012年第16期2413-2415,共3页 Guangdong Medical Journal
基金 广东省深圳市科技计划项目(编号:201003089)
  • 相关文献

参考文献7

  • 1GAN T J. Risk factors for postoperative nausea and vomiting[ J ].Anesth Analg, 2006, 102(6): 1884-1898.
  • 2朱大岭,韩维娜,张荣.细胞色素P_(450)酶系在药物代谢中的作用[J].医药导报,2004,23(7):440-443. 被引量:55
  • 3FURMAN K D, GRIMM D R, MUELLER L, et al. Impact of CYP2D6 intermediate metabolizeralleles on single -dose desipra- mine pharmacokinetics [ J ]. Pharmacogenetics, 2004, 14 (5) : 279 - 284.
  • 4徐建国.防治术后恶心呕吐专家意见[M].北京:中华医学会麻醉学分会,2007.
  • 5BLOWER P R. 5 - HT3 - receptor antagonists and the cytochromeP450 system : clinical implications [ J ]. Cancer J, 2002, 8 ( 5 ) : 405 -414.
  • 6GAN T J. Selective serotonin 5 - HT3 receptor antagonists for post- operative nausea and vomiting: are they all the same? [J]. CNS Drugs, 2005, 19(3) : 225 -238.
  • 7NIELSEN M, OLSEN N V. Genetic polymorphisms in the cyto- chrome P450 system and efficacy of 5 - hydroxytryptamine type 3 receptor antagonists for postoperative nausea and vomiting[ J ]. Br J Anaesth, 2008, 101(4) : 441 -445.

二级参考文献21

  • 1Richardson T H, Griffin K J, Jung F, et al .Targeted antip-eptide antibodies to cytochrome P45[10]2C18 based on epitope mapping of an inhibitory monoclonal antibody to P45[10]2C5[J]. Arch Biochem Biophys, 1997,338(2):157-164.
  • 2Richardson T H, Johnson E F. Alterations of the regiospeci-ficity of progesterone metabolism by the mutagenesis of two key amino acid residues in rabbit cytochrome P45[10]2C3[J]. J Biol Chem, 1994,269(39):23937-23943.
  • 3Lasker J M, Wester M R, Aramsombatdee E,et al. Characte-rization of CYP2C19 and CYP2C9 from human liver: respective roles in microsomal tolbutamide, S-mephenytoin, and omeprazole hydroxylations[J]. Arch Biochem Biophys, 1998,353(1):16-28.
  • 4Venkatakrishnan K, Von M L L, Greenblatt D J. Human drug metabolism and the cytochromes P450: application and relevance of in vitro models[J]. J Clin Pharmacol, 2001,41(11):1149-1179.
  • 5Oates N S, Shah R R, Idle J R, et al. Influence of oxidation polymor-phism on phenformin kinetics and dynamics[J]. Clin Pharmacol Ther, 1993,34(6):827-834.
  • 6Eckhardt K, Li S, Ammon S, et al. Same incidence of adve-rse drug events after codeine adminstration irrespective of the genetically determined differences in morphine formation[J]. Pain, 1998,76(1-2):27-33.
  • 7Miners J Q, Birkett D J.Cytochrome P4502C9: an enzyme of major importance in human drug metabolism[J]. Br J Clin Pharmacol, 1998,45(6):525-538.
  • 8Flockhard D A. Drug interactions and the cytochrome P45[10]sys-tem. the role of cytochrome P45[10]2C19[J]. Clin Pharmaco-kinet, 1995,29(Suppl 1):45-52.
  • 9Daly A K, Brockmo ller J, Broly F, et al.Nomenclature for human CYP2D6 alleles[J]. Pharmacogenetics, 1996,6(3):193-201.
  • 10Ronis M J, Lindros K O, Ingelman S M.The CYP2E[10]subfa-mily, in: Ioannides C[ed]. Cytochromes P450: metabolic and toxicological aspects[M]. New York: Boca Raton, 1996.211-239.

共引文献54

同被引文献28

引证文献3

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部